AI-scale biology is moving from science fiction to funded infrastructure, with more than US$3.1b earmarked for open datasets, lab automation and cloud biology pipelines. That kind of money can reshuffle who supplies the picks and shovels for tomorrow’s drug discovery race and who gets left behind. This article walks through 3 stocks from our Life Sciences Tools & Lab Automation for AI-Scale Biology screener that appear positively exposed to this shift.
The stocks covered below are just a starter pack, and the full screen surfaced 51 more listed lab suppliers with equally detailed stories that are not covered here. To go straight to the broader universe and identify which Life Sciences Tools & Lab Automation for AI-Scale Biology plays best fit your criteria, analyze the Life Sciences Tools & Lab Automation for AI-Scale Biology screener.
Metropolis Healthcare (NSEI:METROPOLIS)
Metropolis Healthcare plugs into the AI-scale biology theme by running high-volume diagnostic labs that generate structured test and imaging data at scale, which can feed future models, while still being a healthcare services play rather than a pure equipment supplier.
Metropolis Healthcare runs a network of pathology and radiology centers offering routine tests, advanced genetics and next-generation sequencing, with all revenue coming from pathology services of about ₹17.1b, and the stock carries a market value around ₹112.3b.
For investors watching how AI-ready diagnostics businesses translate data-heavy operations into earnings power, Metropolis Healthcare is a useful test case.
"Technology investments in automation, AI-supported diagnostics, and end-to-end digitalization are driving operational efficiency, faster turnaround times, and cost optimization. These initiatives are setting the stage for net margin expansion as scale continues to build."
What could matter most now is how one quiet shift in its acquisition and integration pace ultimately filters through to reported profitability.
That quiet shift is exactly what the full narrative for Metropolis Healthcare unpacks, revealing where automation spend, integration risks and earnings power might be quietly decoupling.
Thyrocare Technologies (BSE:539871)
Thyrocare Technologies runs centralized labs that process high volumes of diagnostic tests, feeding the AI-scale biology theme through structured clinical data rather than hardware, with Diagnostic Testing Services contributing about ₹8.2b of its roughly ₹8.8b revenue and the stock valued near ₹81.7b.
For Thyrocare Technologies, the real interest in AI-scale biology is how a high-throughput, nationwide lab grid can turn routine blood work into a rich, recurring data stream that underpins both profit potential and future AI partnerships.
"Accelerated expansion of Thyrocare's franchise network, especially in Tier 2 and Tier 3 cities, is driving higher test volumes and expanding geographic reach, which is likely to deliver sustained revenue growth and operating leverage, thereby supporting both top-line and margin improvement."
What investors will keep watching is how one unresolved pressure on funding and partnerships shapes pricing power just as test volumes climb.
That funding question is exactly what the full narrative for Thyrocare Technologies tackles, showing where accelerating volumes, pricing pressure and partnership terms might quietly reshape Thyrocare Technologies' long term upside.
Molbio Diagnostics (NSEI:MOLBIO)
Molbio Diagnostics sits in the Life Sciences Tools & Lab Automation for AI-Scale Biology theme through its Truenat molecular platform and point-of-care test kits. The company earns about ₹17.5b from diagnostic kits and equipment and has a roughly ₹178b market value.
Molbio Diagnostics turns point-of-care molecular testing into a data engine for AI-driven biology, with Truenat instruments and assays integrated directly into high-throughput diagnostic workflows. Recent earnings momentum, premium P/E and fresh IPO funding all converge on one question: how aggressively management chooses to reinvest in AI-ready diagnostic capacity and margins if a single assumption on demand intensity shifts.
If that reinvestment call is what you care about, unpack how management is weighing capacity, pricing power and AI-readiness in the analysis report for Molbio Diagnostics
Seeking Fresh Alternatives Before They Fly?
Markets move fast and the next breakout themes rarely stay under the radar for long. Scan fresh ideas before momentum gets fully caught and, while it matters, act now.
- Spot resilient businesses before the crowd shifts into safety and review the 225 resilient stocks with low risk scores that aim to keep drawdowns in check when volatility spikes.
- Target income that works harder for you by screening 224 dividend fortresses built around higher yields that could turn steady payouts into meaningful portfolio support.
- Ride the infrastructure backbone of AI by checking 92 AI infrastructure stocks positioned where data centers, chips and energy demand start driving the next wave of capital spending.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com